# Mrna seasonal flu vaccine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine

> The next catalyst for mrna seasonal flu vaccine, sponsored by GSK plc (GSK), is its topline data readout, Jul to Oct 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | mrna seasonal flu vaccine |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Influenza, Human](https://sec-api.dev/indications/influenza-human) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Influenza, Human.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07851246 (A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07851246

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Influenza, Human.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07851246 (A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07851246

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Influenza, Human.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07805707 (A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07805707

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Influenza, Human.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07805707 (A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07805707

## Same indication

- [Flu mrna (formulation a)](https://sec-api.dev/pdufa/flu-mrna-formulation-a) (GSK)
- [Flu mrna (formulation b1)](https://sec-api.dev/pdufa/flu-mrna-formulation-b1) (GSK)
- [Zanamivir](https://sec-api.dev/pdufa/zanamivir) (GSK)

Calendar months: [July 2027](https://sec-api.dev/fda-calendar/2027-07), [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mrna seasonal flu vaccine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine

```bibtex
@misc{secapidev_pdufa_mrna_seasonal_flu_vaccine_20261116,
  title        = {Mrna seasonal flu vaccine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mrna_seasonal_flu_vaccine_20261116","title":"Mrna seasonal flu vaccine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
